Drug Approval | September 09, 2021
Merck’s KEYTRUDA receives China approval for Esophageal cancer
The medicine is now approved for eight indications across five different types of cancer in China.
The medicine is now approved for eight indications across five different types of cancer in China.
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
It is the first branded generic alternative to Fostair 100/6 pMDI
Surgeries for the replacement of hip and knee joints have become common, the ones for the replacement of jaw joints and the use of 3D printed custom-made joints are new
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
Deal signed with AOP Orphan for US commercial rights
A veteran in cell therapy and oncology commercialisation
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Subscribe To Our Newsletter & Stay Updated
